{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:08:51Z","timestamp":1789186131217,"version":"build-2803163510"},"reference-count":28,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,9,10]]},"DOI":"10.1248\/bpb.b26-00303","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:11:39Z","timestamp":1788991899000},"page":"1463-1470","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Therapeutic Impact of Targeting Brk in Epithelial-Derived Cancer Cells"],"prefix":"10.1248","volume":"49","author":[{"given":"Ryohei","family":"Kozaki","sequence":"first","affiliation":[{"name":"Research Center of Oncology, Ono Pharmaceutical Co., Ltd., Osaka 618\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Hotta","sequence":"additional","affiliation":[{"name":"Research Center of Oncology, Ono Pharmaceutical Co., Ltd., Osaka 618\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Teraishi","sequence":"additional","affiliation":[{"name":"Research Center of Oncology, Ono Pharmaceutical Co., Ltd., Osaka 618\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuifang","family":"Li","sequence":"additional","affiliation":[{"name":"Research Center of Oncology, Ono Pharmaceutical Co., Ltd., Osaka 618\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Oritani","sequence":"additional","affiliation":[{"name":"International University of Health and Welfare Narita Hospital, 4\u20133 Kouzunomori, Narita, Chiba 286\u20138686, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J. Clin.<\/i>, <b>74<\/b>, 229\u2013263 (2024).","DOI":"10.3322\/caac.21834"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. <i>Br. Dent. J.<\/i>, <b>233<\/b>, 780\u2013786 (2022).","DOI":"10.1038\/s41415-022-5166-x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ranganath R, Chu Q. Global trends in pancreas cancer among Asia-Pacific population. <i>J. Gastrointest. Oncol.<\/i>, <b>12<\/b> (Suppl. 2), S374\u2013S386 (2021).","DOI":"10.21037\/jgo-20-118"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Dasgupta P, Baade PD, Aitken JF, Ralph N, Chambers SK, Dunn J. Geographical variations in prostate cancer outcomes: a systematic review of international evidence. <i>Front. Oncol.<\/i>, <b>9<\/b>, 238 (2019).","DOI":"10.3389\/fonc.2019.00238"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, Bray F. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. <i>Gut<\/i>, <b>72<\/b>, 338\u2013344 (2023).","DOI":"10.1136\/gutjnl-2022-327736"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tang DD, Ye ZJ, Liu WW, Wu J, Tan JY, Zhang Y, Xu Q, Xiang YB. Survival feature and trend of female breast cancer: a comprehensive review of survival analysis from cancer registration data. <i>Breast<\/i>, <b>79<\/b>, 103862 (2025).","DOI":"10.1016\/j.breast.2024.103862"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Zitricky F, Koskinen AI, Hemminki O, F\u00f6rsti A, Hemminki A, Hemminki K. Survival in oral and pharyngeal cancers is catching up with laryngeal cancer in the NORDIC countries through a half century. <i>Cancer Med.<\/i>, <b>13<\/b>, e6867 (2024).","DOI":"10.1002\/cam4.6867"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Lehrer S, Rheinstein PH. The 5-year relative survival of older patients with prostate cancer is insignificantly different from the 5-year survival of all men of a similar age. <i>Cancer<\/i>, <b>126<\/b>, 2718 (2020).","DOI":"10.1002\/cncr.32788"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Jiang Y, Yuan H, Li Z, Ji X, Shen Q, Tuo J, Bi J, Li H, Xiang Y. Global pattern and trends of colorectal cancer survival: a systematic review of population-based registration data. <i>Cancer Biol. Med.<\/i>, <b>19<\/b>, 175\u2013186 (2021).","DOI":"10.20892\/j.issn.2095-3941.2020.0634"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Mitra A, Mishra L, Li S. EMT, CTCs and CSCs in tumor relapse and drug-resistance. <i>Oncotarget<\/i>, <b>6<\/b>, 10697\u201310711 (2015).","DOI":"10.18632\/oncotarget.4037"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. <i>Cancer Drug Resist.<\/i>, <b>2<\/b>, 141\u2013160 (2019).","DOI":"10.20517\/cdr.2019.10"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ang HL, Yuan Y, Lai X, Tan TZ, Wang L, Huang BB, Pandey V, Huang RH, Lobie PE, Goh BC, Sethi G, Yap CT, Chan CW, Lee SC, Kumar AP. Putting the BRK on breast cancer: from molecular target to therapeutics. <i>Theranostics<\/i>, <b>11<\/b>, 1115\u20131128 (2021).","DOI":"10.7150\/thno.49716"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Xiang B, Chatti K, Qiu H, Lakshmi B, Krasnitz A, Hicks J, Yu M, Miller WT, Muthuswamy SK. Brk is coamplified with ErbB2 to promote proliferation in breast cancer. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>105<\/b>, 12463\u201312468 (2008).","DOI":"10.1073\/pnas.0805009105"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Burmi RS, Box GM, Wazir U, Hussain HA, Davies JA, Court WJ, Eccles SA, Jiang WG, Mokbel K, Harvey AJ. Breast tumour kinase (Brk\/PTK6) contributes to breast tumour xenograft growth and modulates chemotherapeutic responses. <i>Genes<\/i>, <b>13<\/b>, 402 (2022).","DOI":"10.3390\/genes13030402"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Jiang J, Gui F, He Z, <i>et al<\/i>. Targeting BRK-positive breast cancers with small-molecule kinase inhibitors. <i>Cancer Res.<\/i>, <b>77<\/b>, 175\u2013186 (2017).","DOI":"10.1158\/0008-5472.CAN-16-1038"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Martinez C, Xiong Y, Bartkowski A, Harada I, Ren X, Byerly J, Port E, Jin J, Irie H. A PROTAC degrader suppresses oncogenic functions of PTK6, inducing apoptosis of breast cancer cells. <i>Cell Chem. Biol.<\/i>, <b>32<\/b>, 255\u2013266.e8 (2025).","DOI":"10.1016\/j.chembiol.2024.10.008"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Alwanian WM, Vlajic K, Bie W, Kajdacsy-Balla A, Tyner AL. Protein tyrosine kinase 6 regulates activation of SRC kinase. <i>J. Biol. Chem.<\/i>, <b>298<\/b>, 102584 (2022).","DOI":"10.1016\/j.jbc.2022.102584"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GB, Hung MC, Fan Z. Brk\/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. <i>Oncogene<\/i>, <b>31<\/b>, 4372\u20134383 (2012).","DOI":"10.1038\/onc.2011.608"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Gierut JJ, Mathur PS, Bie W, Han J, Tyner AL. Targeting protein tyrosine kinase 6 enhances apoptosis of colon cancer cells following DNA damage. <i>Mol. Cancer Ther.<\/i>, <b>11<\/b>, 2311\u20132320 (2012).","DOI":"10.1158\/1535-7163.MCT-12-0009"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ono H, Basson MD, Ito H. PTK6 promotes cancer migration and invasion in pancreatic cancer cells dependent on ERK signaling. <i>PLOS ONE<\/i>, <b>9<\/b>, e96060 (2014).","DOI":"10.1371\/journal.pone.0096060"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Ostrander JH, Daniel AR, Lange CA. Brk\/PTK6 signaling in normal and cancer cell models. <i>Curr. Opin. Pharmacol.<\/i>, <b>10<\/b>, 662\u2013669 (2010).","DOI":"10.1016\/j.coph.2010.08.007"},{"key":"22","unstructured":"22) Bourton EC, Hussain H, Plowman PN, Harvey AJ, Parris CN. Radiosensitivity of human breast cancer cell lines expressing the breast tumor kinase (Brk). <i>J. Cancer Sci. Ther.<\/i>, <b>7<\/b>, 95\u2013101 (2015)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Wong WR, Oliver AG, Linington RG. Development of antibiotic activity profile screening for the classification and discovery of natural product antibiotics. <i>Chem. Biol.<\/i>, <b>19<\/b>, 1483\u20131495 (2012).","DOI":"10.1016\/j.chembiol.2012.09.014"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Gilic MB, Tyner AL. Targeting protein tyrosine kinase 6 in cancer. <i>Biochim. Biophys. Acta. Rev. Cancer<\/i>, <b>1874<\/b>, 188432 (2020).","DOI":"10.1016\/j.bbcan.2020.188432"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Qin Z, Wang R, Hou P, Zhang Y, Yuan Q, Wang Y, Yang Y, Xu T. TCR signaling induces STAT3 phosphorylation to promote TH17 cell differentiation. <i>J. Exp. Med.<\/i>, <b>221<\/b>, e20230683 (2024).","DOI":"10.1084\/jem.20230683"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Kitabayashi C, Fukada T, Kanamoto M, Ohashi W, Hojyo S, Atsumi T, Ueda N, Azuma I, Hirota H, Murakami M, Hirano T. Zinc suppresses Th17 development <i>via<\/i> inhibition of STAT3 activation. <i>Int. Immunol.<\/i>, <b>22<\/b>, 375\u2013386 (2010).","DOI":"10.1093\/intimm\/dxq017"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Ma YF, Chen C, Li D, Liu M, Lv ZW, Ji Y, Xu J. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. <i>Oncotarget<\/i>, <b>8<\/b>, 7614\u20137624 (2017).","DOI":"10.18632\/oncotarget.13819"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Liu C, Liu R, Wang B, Lian J, Yao Y, Sun H, Zhang C, Fang L, Guan X, Shi J, Han S, Zhan F, Luo S, Yao Y, Zheng T, Zhang Y. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. <i>J. Immunother. Cancer<\/i>, <b>9<\/b>, e001895 (2021).","DOI":"10.1136\/jitc-2020-001895"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00303\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:26:31Z","timestamp":1789183591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00303\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00303","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"b26-00303"}}